EUVIMEDEUVIMED entdecken
Crossref

Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States

Nikhil T Sebastian iD, Dattatraya Patil iD, Pretesh R Patel, Ashesh B Jani, Bruce W Hershatter, Vishal R Dhere, Karen D Godette, C Adam Lorentz iD, Aaron D Weiss, Shreyas S Joshi iD, Martin G Sanda, Sagar A Patel

Cancer · 2025

DOI: 10.1002/cncr.35795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Nikhil T Sebastian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Health Expenditures, Health Care Costs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Prostate Cancer Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radical prostatectomy (RP) and radiotherapy (RT) are standard‐of‐care treatments for localized prostate cancer. The authors studied the utilization and total health care and patient‐incurred costs of RP and RT in the United States using the Merative MarketScan Medicare (Medicare Supplemental and Coordination of Benefits [MDCR]) and Commercial (Commercial Claims and Encounters [CCAE]) databases.

Methods

Men were identified who had nonmetastatic prostate cancer treated with RP, external‐beam RT (EBRT), brachytherapy (BT), EBRT combined with BT (EBRT + BT), stereotactic body RT (SBRT), or proton‐beam therapy (PBT) between 2009 and 2022. Year‐to‐year treatment utilization was compared using the Kendall Tau‐b test. Mean total health care and patient out‐of‐pocket costs within 12 months of treatment were compared using the Kruskal–Wallis test.

Results

In the MDCR database, 44,937 patients were identified who received treatment with RP ( n = 12,879), EBRT ( n = 26,193), BT ( n = 926), EBRT + BT ( n = 4706), PBT ( n = 57), or SBRT ( n = 176). Between 2009 and 2021, EBRT use increased from 52.5% to 62.2% ( p for trend < .001), SBRT increased from 0.4% to 0.5% ( p < .001), BT decreased from 3.1% to 1.0% ( p < .001), and EBRT + BT decreased from 14.8% to 6.8% ( p < 0.001); whereas use remained similar for RP (from 29.1% to 29.4%; p = .82) and PBT (from 0.1% to 0.1%; p = .93). In the CCAE database, 75,626 patients were identified who received treatment with RP ( n = 50,278), EBRT ( n = 16,985), BT ( n = 1243), EBRT + BT ( n = 6811), PBT ( n = 92), or SBRT ( n = 217). EBRT use increased from 20.0% to 24.9% ( p < .001), SBRT increased from 0.1% to 0.8% ( p < .001), BT decreased from 2.5% to 0.7% ( p < .001), and EBRT + BT decreased from 10.6% to 7.4% ( p < .001); whereas use remained similar for RP (from 66.8% to 66.1%; p for trend = .82), and PBT (from 0.1% to 0.1%; p for trend = .76). In the MDCR and CCAE databases, PBT had the highest total cost, whereas BT had the lowest.

Conclusions

Between 2009 and 2021, there was increasing use of EBRT and SBRT, whereas use of RP remained stable. Although BT was the least costly, its utilization as monotherapy and combined with EBRT declined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHealth ExpendituresHealth Care CostsHumansMaleUnited StatesAgedProstatectomyBrachytherapyMedicareRadiosurgeryAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

brachytherapycostexternal‐beam radiation therapyprostate cancerprostatectomyproton therapystereotactic body radiation therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Department of Urology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Nikhil T Sebastian, Dattatraya Patil, C Adam Lorentz, Shreyas S Joshi

Förderung

  • Prostate Cancer Foundation
  • NIH HHS

Zitieren

APA

Sebastian, N. T., Patil, D., Patel, P. R., Jani, A. B., Hershatter, B. W., Dhere, V. R., Godette, K. D., Lorentz, C. A., Weiss, A. D., Joshi, S. S., Sanda, M. G., & Patel, S. A. (2025). Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. Cancer. https://doi.org/10.1002/cncr.35795

Vancouver

Sebastian NT, Patil D, Patel PR, Jani AB, Hershatter BW, Dhere VR, et al. Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. Cancer. 2025. doi:10.1002/cncr.35795

BibTeX
@article{Sebastian2025,
  author = {Sebastian, Nikhil T and Patil, Dattatraya and Patel, Pretesh R and Jani, Ashesh B and Hershatter, Bruce W and Dhere, Vishal R and Godette, Karen D and Lorentz, C Adam and Weiss, Aaron D and Joshi, Shreyas S and Sanda, Martin G and Patel, Sagar A},
  title = {Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35795}
}
Kostenlos starten →